Hwee Teoh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7677423/publications.pdf

Version: 2024-02-01

124 papers	6,568 citations	81434 41 h-index	78623 77 g-index
125 all docs	125 docs citations	125 times ranked	13380 citing authors

#	Article	IF	Citations
1	Mitral repair with leaflet preservation versus leaflet resection and ventricular reverse remodeling from a randomized trial. Journal of Thoracic and Cardiovascular Surgery, 2023, 166, 74-83.e2.	0.4	8
2	A randomized trial comparing axillary versus innominate artery cannulation for aortic arch surgery. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 1426-1438.e2.	0.4	17
3	Leaflet Resection vs Preservation for Degenerative Mitral Regurgitation: Functional Outcomes and Mitral Stenosis at 12 Months in a Randomized Trial. Canadian Journal of Cardiology, 2022, 38, 808-814.	0.8	3
4	Empagliflozin does not affect left ventricular diastolic function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial. Acta Diabetologica, 2022, 59, 575.	1.2	4
5	Glycemic Control and Cardiovascular Risk Factor Management in Adults With Type 2 Diabetes With and Without Chronic Kidney Disease Before Sodium-Glucose Cotransporter Protein 2 Inhibitors: Insights From the Diabetes Mellitus Status in Canada Survey. Canadian Journal of Diabetes, 2021, , .	0.4	1
6	Isolation and characterization of circulating pro-vascular progenitor cell subsets from human whole blood samples. STAR Protocols, 2021, 2, 100311.	0.5	5
7	Loss of endothelial cell-specific autophagy-related protein 7 exacerbates doxorubicin-induced cardiotoxicity. Biochemistry and Biophysics Reports, 2021, 25, 100926.	0.7	5
8	Life and limb protection with dual anti-thrombotic pathway inhibition: COMPASS ushers in a new day in atherothrombotic risk reduction. Med, 2021, 2, 233-242.	2.2	1
9	Lessons from bariatric surgery: Can increased GLP-1 enhance vascular repair during cardiometabolic-based chronic disease?. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 1171-1188.	2.6	17
10	Effect of Continuous Electrocardiogram Monitoring on Detection of Undiagnosed Atrial Fibrillation After Hospitalization for Cardiac Surgery. JAMA Network Open, 2021, 4, e2121867.	2.8	24
11	A randomized trial of icosapent ethyl in ambulatory patients with COVID-19. IScience, 2021, 24, 103040.	1.9	19
12	Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation, 2020, 141, 704-707.	1.6	225
13	Randomized, Controlled Trial Comparing Mitral Valve Repair With Leaflet Resection Versus Leaflet Preservation on Functional Mitral Stenosis. Circulation, 2020, 142, 1342-1350.	1.6	25
14	The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. Nephrology Dialysis Transplantation, 2020, 35, 895-897.	0.4	22
15	Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial. Journal of the American Society of Echocardiography, 2020, 33, 644-646.	1.2	18
16	Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis. Metabolism Open, 2020, 7, 100039.	1.4	14
17	The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension. Biochemical and Biophysical Research Communications, 2020, 524, 50-56.	1.0	69
18	Vascular Risk Reduction in Obesity through Reduced Granulocyte Burden and Improved Angiogenic Monocyte Content following Bariatric Surgery. Cell Reports Medicine, 2020, 1, 100018.	3.3	16

#	Article	IF	Citations
19	Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation, 2019, 140, 1693-1702.	1.6	371
20	SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus. Cell Metabolism, 2019, 30, 609-613.	7.2	69
21	Empagliflozin restores the integrity of the endothelial glycocalyx in vitro. Molecular and Cellular Biochemistry, 2019, 459, 121-130.	1.4	36
22	Vascular Regenerative Cell Exhaustion in Diabetes: Translational Opportunities to Mitigate Cardiometabolic Risk. Trends in Molecular Medicine, 2019, 25, 640-655.	3.5	19
23	Circulating Pro-Vascular Progenitor CellÂDepletion During Type 2 Diabetes. JACC Basic To Translational Science, 2019, 4, 98-112.	1.9	21
24	A novel role of endothelial autophagy as a regulator of myocardial fatty acid oxidation. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 185-193.	0.4	9
25	Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial. Diabetes Care, 2019, 42, 173-176.	4.3	81
26	Loss of vascular smooth muscle cell autophagy exacerbates angiotensin II-associated aortic remodeling. Journal of Vascular Surgery, 2018, 68, 859-871.	0.6	32
27	Blood Pressure Management in Adults With Type 2 Diabetes: Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey. Canadian Journal of Diabetes, 2018, 42, 130-137.	0.4	25
28	Role of Endothelium in Doxorubicin-Induced Cardiomyopathy. JACC Basic To Translational Science, 2018, 3, 861-870.	1.9	98
29	Empagliflozin Increases Cardiac EnergyÂProductionÂin Diabetes. JACC Basic To Translational Science, 2018, 3, 575-587.	1.9	263
30	Canagliflozin Improves the Recovery of Blood Flow in an Experimental Model of Severe LimbÂIschemia. JACC Basic To Translational Science, 2018, 3, 327-329.	1.9	19
31	Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis. CMAJ Open, 2017, 5, E152-E177.	1.1	57
32	Axillary versus innominate artery cannulation for antegrade cerebral perfusion in aortic surgery: design of the Aortic Surgery Cerebral Protection Evaluation (ACE) CardioLink-3 randomised trial. BMJ Open, 2017, 7, e014491.	0.8	19
33	Endothelial-specific deletion of autophagy-related 7 (ATG7) attenuates arterial thrombosis in mice. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 978-988.e1.	0.4	22
34	Cardiovascular inflammation is reduced with methotrexate in diabetes. Molecular and Cellular Biochemistry, 2017, 432, 159-167.	1.4	14
35	Endothelial long non-coding RNAs regulated by oxidized LDL. Molecular and Cellular Biochemistry, 2017, 431, 139-149.	1.4	23
36	Randomised trial of mitral valve repair with leaflet resection versus leaflet preservation on functional mitral stenosis (The CAMRA CardioLink-2 Trial). BMJ Open, 2017, 7, e015032.	0.8	12

#	Article	IF	Citations
37	Investigation of TGFÎ²1-Induced Long Noncoding RNAs in Endothelial Cells. International Journal of Vascular Medicine, 2016, 2016, 1-12.	0.4	15
38	Frequency of cancer events with saxagliptin in the <scp>SAVORâ€TIMI</scp> 53 trial. Diabetes, Obesity and Metabolism, 2016, 18, 186-190.	2.2	25
39	Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?. Diabetes Care, 2016, 39, e212-e213.	4.3	190
40	Investigation of novel LPS-induced differentially expressed long non-coding RNAs in endothelial cells. Molecular and Cellular Biochemistry, 2016, 421, 157-168.	1.4	26
41	A global profile of glucose-sensitive endothelial-expressed long non-coding RNAs. Canadian Journal of Physiology and Pharmacology, 2016, 94, 1007-1014.	0.7	23
42	Glycaemic control and cardiovascular risk factor management in patients with diabetes with and without coronary artery disease: insights from the diabetes mellitus status in Canada survey. European Heart Journal Quality of Care & Clinical Outcomes, 2016, 2, 277-284.	1.8	14
43	Adiponectin limits monocytic microparticle-induced endothelial activation by modulation of the AMPK, Akt and NFÎºB signaling pathways. Atherosclerosis, 2016, 245, 1-11.	0.4	25
44	Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials. BMC Surgery, 2015, 15, 112.	0.6	63
45	Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovascular Disorders, 2015, 15, 96.	0.7	108
46	Endothelial cell control of thrombosis. BMC Cardiovascular Disorders, 2015, 15, 130.	0.7	500
47	Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes. Canadian Journal of Diabetes, 2015, 39, S148-S154.	0.4	26
48	Effects of long-term chloroquine administration on the natural history of aortic aneurysms in mice. Canadian Journal of Physiology and Pharmacology, 2015, 93, 641-648.	0.7	10
49	Current and Emerging Pharmacotherapies for Weight Management in Prediabetes and Diabetes. Canadian Journal of Diabetes, 2015, 39, S134-S141.	0.4	17
50	The Essential Autophagy Gene ATG7 Modulates Organ Fibrosis via Regulation of Endothelial-to-Mesenchymal Transition. Journal of Biological Chemistry, 2015, 290, 2547-2559.	1.6	87
51	Non-melanoma Skin Cancer in Canada Chapter 2: Primary Prevention of Non-melanoma Skin Cancer. Journal of Cutaneous Medicine and Surgery, 2015, 19, 216-226.	0.6	10
52	Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial. Diabetes Care, 2015, 38, 1145-1153.	4.3	73
53	Dual antiplatelet therapy use by Canadian cardiac surgeons. Journal of Thoracic and Cardiovascular Surgery, 2015, 150, 1548-1554.e3.	0.4	27
54	Obesity and Atherosclerosis: Mechanistic Insights. Canadian Journal of Cardiology, 2015, 31, 177-183.	0.8	149

#	Article	IF	Citations
55	Pedicled no-touch saphenous vein graft harvest limits vascular smooth muscle cell activation: the PATENT saphenous vein graft studyâ€. European Journal of Cardio-thoracic Surgery, 2014, 45, 717-725.	0.6	81
56	Autophagy gene fingerprint in human ischemia and reperfusion. Journal of Thoracic and Cardiovascular Surgery, 2014, 147, 1065-1072.e1.	0.4	43
57	BRCA1 shields vascular smooth muscle cells from oxidative stress. Journal of Thoracic and Cardiovascular Surgery, 2014, 147, 1946-1955.e1.	0.4	20
58	Regulating cardiac energy metabolism and bioenergetics by targeting the DNA damage repair protein BRCA1. Journal of Thoracic and Cardiovascular Surgery, 2013, 146, 702-709.	0.4	19
59	Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes and Endocrinology,the, 2013, 1, 317-328.	5.5	195
60	BRCA1 is a novel target to improve endothelial dysfunction and retard atherosclerosis. Journal of Thoracic and Cardiovascular Surgery, 2013, 146, 949-960.e4.	0.4	48
61	Type 2 Diabetes Mellitus Management in Canada: Is It Improving?. Canadian Journal of Diabetes, 2013, 37, 82-89.	0.4	127
62	BRCA1 gene therapy reduces systemic inflammatory response and multiple organ failure and improves survival in experimental sepsis. Gene Therapy, 2013, 20, 51-61.	2.3	23
63	Benefits of Modest Weight Loss on the Management of Type 2 Diabetes Mellitus. Canadian Journal of Diabetes, 2013, 37, 128-134.	0.4	61
64	Identification and Management of Patients at Elevated Cardiometabolic Risk in Canadian Primary Care: How Well Are We Doing?. Canadian Journal of Cardiology, 2013, 29, 960-968.	0.8	18
65	A comparison of the assessment and management of cardiometabolic risk in patients with and without type 2 diabetes mellitus in Canadian primary care. Diabetes, Obesity and Metabolism, 2013, 15, 1093-1100.	2.2	14
66	BRCA2 Protein Deficiency Exaggerates Doxorubicin-induced Cardiomyocyte Apoptosis and Cardiac Failure. Journal of Biological Chemistry, 2012, 287, 6604-6614.	1.6	41
67	MicroRNA-145 Targeted Therapy Reduces Atherosclerosis. Circulation, 2012, 126, S81-90.	1.6	237
68	Assessment and Treatment of Cardiometabolic Risk in Adults at Risk for or with Type 2 Diabetes Mellitus. Canadian Journal of Diabetes, 2012, 36, 320-326.	0.4	0
69	Perceptions of Canadian Primary Care Physicians Towards Cardiovascular Risk Assessment and Lipid Management. Canadian Journal of Cardiology, 2012, 28, 14-19.	0.8	37
70	Poor achievement of guidelines-recommended targets in type 2 diabetes: findings from a contemporary prospective cohort study. International Journal of Clinical Practice, 2012, 66, 457-464.	0.8	37
71	Managing cardiometabolic risk in primary care: summary of the 2011 consensus statement. Canadian Family Physician, 2012, 58, 389-93, e196-201.	0.1	20
72	The effects of rosiglitazone on inflammatory biomarkers and adipokines in diabetic, hypertensive patients. Experimental and Clinical Cardiology, 2012, 17, 191-6.	1.3	2

#	Article	IF	Citations
73	Should A1C Targets Be Individualized for All People With Diabetes?. Diabetes Care, 2011, 34, S191-S196.	4.3	16
74	Use of a Treatment Optimization Algorithm Involving Statin-Ezetimibe Combination Aids in Achievement of Guideline-Based Low-Density Lipoprotein Targets in Patients With Dyslipidemia at High Vascular Risk Guideline-Based Undertaking to Improve Dyslipidemia Management in Canada (GUIDANC). Canadian Journal of Cardiology, 2011, 27, 138-145.	0.8	6
75	Cardiometabolic Risk in Canada: A Detailed Analysis and Position Paper by the Cardiometabolic Risk Working Group. Canadian Journal of Cardiology, 2011, 27, e1-e33.	0.8	138
76	Identification and Management of Cardiometabolic Risk in Canada: A Position Paper by the Cardiometabolic Risk Working Group (Executive Summary). Canadian Journal of Cardiology, 2011, 27, 124-131.	0.8	48
77	Herceptin, a recombinant humanized anti-ERBB2 monoclonal antibody, induces cardiomyocyte death. Biochemical and Biophysical Research Communications, 2011, 411, 421-426.	1.0	16
78	Effects on duration of post-operative ischemia and patterns of blood flow recovery in different conditions of mouse hind limb ischemia. Vascular Cell, 2011, 3, 14.	0.2	2
79	Should C-Reactive Protein Be a Target of Therapy?. Diabetes Care, 2011, 34, S155-S160.	4.3	24
80	BRCA1 is an essential regulator of heart function and survival following myocardial infarction. Nature Communications, 2011, 2, 593.	5.8	114
81	Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. European Heart Journal, 2011, 32, 2135-2142.	1.0	74
82	Effects of Ezetimibe Add-on to Statin Therapy on Adipokine Production in Patients With Metabolic Syndrome and Stable Vascular Disease. Journal of Cardiovascular Pharmacology, 2010, 56, 241-245.	0.8	9
83	Adropin Is a Novel Regulator of Endothelial Function. Circulation, 2010, 122, S185-92.	1.6	213
84	Patient Age, Ethnicity, Medical History, and Risk Factor Profile, but Not Drug Insurance Coverage, Predict Successful Attainment of Glycemic Targets. Diabetes Care, 2010, 33, 2558-2560.	4.3	10
85	Adiponectin primes human monocytes into alternative anti-inflammatory M2 macrophages. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 299, H656-H663.	1.5	186
86	Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada. Canadian Journal of Cardiology, 2010, 26, 297-302.	0.8	89
87	DNA damage repair and cardiovascular diseases. Canadian Journal of Cardiology, 2010, 26, 13A-16A.	0.8	34
88	Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: translational implications for atherosclerosis. American Journal of Physiology - Endocrinology and Metabolism, 2009, 296, E1440-E1449.	1.8	94
89	Usefulness of Statinâ€“Ezetimibe Combination to Reduce the Care Gap in Dyslipidemia Management in Patients With a High Risk of Atherosclerotic Disease. American Journal of Cardiology, 2009, 104, 798-804.e2.	0.7	15
90	Statin Effects on LDL and HDL Cholesterol in South Asian and White Populations. Journal of Clinical Pharmacology, 2009, 49, 831-837.	1.0	25

#	Article	IF	Citations
91	Vascular effects of estrone and diethylstilbestrol in porcine coronary arteries. Menopause, 2009, 16, 104-109.	0.8	12
92	Impaired endothelial function in C-reactive protein overexpressing mice. Atherosclerosis, 2008, 201, 318-325.	0.4	69
93	Vascular biology of adiponectin. Canadian Journal of Cardiology, 2008, 24, 18C-21C.	0.8	4
94	Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 295, H1377-H1384.	1.5	267
95	Adiponectin deficiency promotes endothelial activation and profoundly exacerbates sepsis-related mortality. American Journal of Physiology - Endocrinology and Metabolism, 2008, 295, E658-E664.	1.8	104
96	Induction of matrix metalloproteinase-2 enhances systemic arterial contraction after hypoxia. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 292, H684-H693.	1.5	13
97	Adiponectin and cardiovascular disease: state of the art?. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 292, H1655-H1663.	1.5	146
98	Vascular dysfunction: a Janus face of visfatin in diabetes?. Metabolism: Clinical and Experimental, 2007, 56, 459-461.	1.5	5
99	C-reactive protein, metabolic syndrome, and end organ damage. Metabolism: Clinical and Experimental, 2007, 56, 1620-1622.	1.5	10
100	NON-GENOMIC VASCULAR ACTIONS OF FEMALE SEX HORMONES: PHYSIOLOGICAL IMPLICATIONS AND SIGNALLING PATHWAYS. Clinical and Experimental Pharmacology and Physiology, 2007, 34, 822-826.	0.9	21
101	Does C-reactive protein predict saphenous vein graft patency?. Journal of Thoracic and Cardiovascular Surgery, 2007, 134, 277-279.	0.4	1
102	Adiponectin and myocardial infarction: a paradox or a paradigm?. European Heart Journal, 2006, 27, 2266-2268.	1.0	46
103	Interaction between endothelial heme oxygenase-2 and endothelin-1 in altered aortic reactivity after hypoxia in rats. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 288, H962-H970.	1.5	20
104	Hypoxia induces a functionally significant and translationally efficient neuronal NO synthase mRNA variant. Journal of Clinical Investigation, 2005, 115, 3128-3139.	3.9	98
105	Phytoestrogens and Cardiovascular Disorders. Progress in Experimental Cardiology, 2004, , 513-524.	0.0	0
106	Role of Clâ^' currents in rat aortic smooth muscle activation by prostaglandin F2Î±. European Journal of Pharmacology, 2003, 481, 133-140.	1.7	3
107	Increased myofibrillar protein phosphatase-1 activity impairs rat aortic smooth muscle activation after hypoxia. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 284, H1182-H1189.	1.5	9
108	Mechanisms of aortic smooth muscle hyporeactivity after prolonged hypoxia in rats. Journal of Applied Physiology, 2002, 92, 2625-2632.	1.2	7

#	Article	IF	Citations
109	Inhibition of prostanoid-mediated contraction to endothelin-1 after hypoxia in rat aorta. European Journal of Pharmacology, 2001, 423, 57-61.	1.7	6
110	Differential effects of 17Î² -estradiol and testosterone on the contractile responses of porcine coronary arteries. British Journal of Pharmacology, 2000, 129, 1301-1308.	2.7	87
111	Enhanced relaxation of porcine coronary arteries after acute exposure to a physiological level of 17Î²-estradiol involves non-genomic mechanisms and the cyclic AMP cascade. British Journal of Pharmacology, 2000, 129, 1739-1747.	2.7	36
112	Interactions between Panax quinquefolium saponins and vitamin C are observed in vitro. Molecular and Cellular Biochemistry, 2000, 204, 77-82.	1.4	18
113	Acute impairment of relaxation by low levels of testosterone in porcine coronary arteries. Cardiovascular Research, 2000, 45, 1010-1018.	1.8	34
114	Short-term exposure to physiological levels of 17Î²-estradiol enhances endothelium-independent relaxation in porcine coronary artery. Cardiovascular Research, 1999, 42, 224-231.	1.8	47
115	ACUTE EXPOSURE TO A LOW LEVEL OF TESTOSTERONE IMPAIRS RELAXATION IN PORCINE CORONARY ARTERIES. Clinical and Experimental Pharmacology and Physiology, 1999, 26, 830-832.	0.9	19
116	Progesterone modulates estradiol actions: acute effects at physiological concentrations. European Journal of Pharmacology, 1999, 378, 57-62.	1.7	18
117	Low concentrations of 17Î²-estradiol reduce oxidative modification of low-density lipoproteins in the presence of vitamin C and vitamin E. Free Radical Biology and Medicine, 1999, 27, 438-441.	1.3	21
118	Panax quinquefolium saponins protects low density lipoproteins from oxidation. Life Sciences, 1998, 64, 53-62.	2.0	43
119	ENDOTHELIAL DYSFUNCTION EXACERBATES THE IMPAIRMENT OF RELAXATION BY LYSOPHOSPHATIDYLCHOLINE IN PORCINE CORONARY ARTERY. Clinical and Experimental Pharmacology and Physiology, 1997, 24, 984-986.	0.9	11
120	GABA, glutamate and substance Pâ€like immunoreactivity release: effects of novel GABA_B antagonists. British Journal of Pharmacology, 1996, 118, 1153-1160.	2.7	61
121	Evidence for release of glutamic acid, aspartic acid and substance P but not Î³-aminobutyric acid from primary afferent fibres in rat spinal cord. European Journal of Pharmacology, 1996, 302, 27-36.	1.7	28
122	Chronic (-)baclofen or CGP 36742 alters GABAB receptor sensitivity in rat brain and spinal cord. NeuroReport, 1995, 6, 399.	0.6	39
123	Effect of lamotrigine on the electrically-evoked release of endogenous amino acids from slices of dorsal horn of the rat spinal cord. Neuropharmacology, 1995, 34, 1273-1278.	2.0	54
124	Stageâ€based approach to predict left ventricular reverse remodeling after mitral repair. Clinical Cardiology, 0, , .	0.7	4